Online First Articles

Abstract: Background: Recurrent pregnancy loss (RPL) associated with endometrial dysfunction remains clinically challenging due to the lack of localized, multifunctional therapeutic strategies. Restoring endometrial receptivity, vascularization, and immune balance is key to successful intervention. Methods: An injectable bioactive hydrogel was developed by crosslinking aldehyde-modified hyaluronic acid (HA-CHO) with chitosan. The hydrogel was loaded with LIF (Leukemia Inhibitory Factor), VEGF (Vascular Endothelial Growth Factor), IL-11 (Interleukin-11), and valproic acid to enhance regenerative activity. Its effects were assessed in vitro via cell proliferation (CCK-8), tube formation (HUVEC assay), cytokine expression (THP-1 qPCR), and endometrial gene profiling (hEMSC qPCR). Results: The hydrogel exhibited rapid gelation, good biocompatibility, and factor-loading capacity. It significantly enhanced hEMSC proliferation and HUVEC tube formation. Pro-inflammatory cytokines (TNF-α, IL-6) were downregulated, while IL-10 (Interleukin-10) was upregulated in macrophages. The hydrogel also increased expression of LIF and IGFBP1 (Insulin-like Growth Factor Binding Protein 1), but not PRL, indicating enhanced receptivity without full decidualization. Conclusion: This HA-CHO/chitosan hydrogel supports endometrial regeneration through coordinated promotion of proliferation, angiogenesis, immune modulation, and receptivity. It holds strong potential for localized treatment of RPL with endometrial insufficiency.

Abstract: This in vitro study performed a comparative mechanical evaluation of three classes of direct restorative materials: resin composites, polyacid-modified composite resins (components), and Glass Ionomer Cements (GICs). The objective was to clarify the mechanical position of components relative to composites and glass ionomer cements (GICs). Specimens from two materials per class including the components Dyract AP and Dyract Extra were fabricated using standardized molds. Compressive, diametral tensile, and three-point flexural strength tests were conducted according to ADA and ISO specifications, followed by statistical analysis using ANOVA and Tukey’s HSD test. Results established a consistent mechanical hierarchy: composite resins exhibited the highest strength values in all tests, followed by components, with GICs demonstrating the lowest. Within the component group, the thirdgeneration Dyract Extra showed superior properties compared to Dyract AP. The findings confirm that components occupy an intermediate mechanical position, offering significantly greater strength than GICs but not matching composites. Thus, components suit low-to-moderate stress applications where fluoride release and handling ease are beneficial, while composites remain indicated for high-stress areas. This study provides clear evidence for evidence-based clinical material selection.

Abstract: Background: Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, and the development of effective, targeted drug delivery systems is crucial to improve therapeutic outcomes. Graphene oxide (GO)-based nanocarriers have shown promise for controlled drug release, yet their biological evaluation remains limited. Methods: We synthesized a composite nanoparticle system by electrostatic self-assembly of chitosan (CS) onto graphene oxide (GO), followed by doxorubicin (DOX) loading. The resulting GO–CS–DOX nanoparticles were characterized by transmission electron microscopy (TEM), dynamic light scattering (DLS), zeta potential, and pHresponsive release profiles. Preliminary biological performance was evaluated in gastric cancer cells (AGS), including dose–response cytotoxicity and fluorescence-based uptake studies. Results: GO–CS– DOX nanoparticles showed a clear pH-dependent DOX release behavior, with accelerated release under mildly acidic conditions. DLS and zeta potential measurements confirmed successful drug loading and changes in surface charge. In vitro, GO–CS–DOX demonstrated comparable or slightly enhanced cytotoxicity relative to free DOX at specific concentrations. Cellular uptake of DOX was observed under acidic conditions, consistent with lysosomal trafficking. However, only preliminary in vitro data were collected and no mechanistic apoptosis studies were performed. Conclusion: This study presents the design and initial evaluation of a pH-responsive GO–CS–DOX nanocarrier. While the in vitro results indicate potential for controlled drug release and tumor-targeted delivery, the biological findings are still limited and should be interpreted as preliminary. Further in-depth studies, including apoptosis assays and in vivo validation, are necessary to fully establish therapeutic efficacy.

Abstract: Background: Postoperative wound sealing and localized drug delivery are critical needs in nasopharyngeal carcinoma (NPC) management. Natural polysaccharide-based films offer a biocompatible platform for addressing these challenges. Methods: A composite film was prepared by Schiff base crosslinking of chitosan and oxidized pullulan. The film was characterized by FTIR, and its adhesion, drug release, cytocompatibility, and effects on cell migration were evaluated using in vitro assays. Results: The composite film exhibited a distinct C=N peak in FTIR spectra and significantly enhanced wet adhesion (55 kPa) compared to individual components. Cisplatin-loaded films showed sustained release over 72 h and reduced the viability of CNE-2 cells to 28%. The drug-free film was non-cytotoxic. Extracts from the composite film promoted nasopharyngeal epithelial cell migration, as shown by RTCA assay. Conclusion: This study explored the in vitro characteristics of a chitosan/oxidized pullulan film and evaluated its basic biological performance at the cellular level capable of localized drug release and supporting cell-level healing responses. Further validation in more complex models is warranted.

Abstract: Background: Antiphospholipid syndrome (APS) is a major cause of pregnancy morbidity, characterized by antiphospholipid antibody–induced platelet activation and placental thrombosis. Integrin αIIbβ3 is a key mediator of platelet aggregation in this pathological process. Methods: We developed PEGDA-based hydrogels functionalized with acrylated RGD peptides to competitively bind αIIbβ3 and inhibit platelet aggregation. The effects of hydrogel and αIIbβ3 antibody treatments were evaluated in vitro using integrin-binding assays, turbidity-based platelet aggregation and clotting assays, ELISA for cytokine release, and transwell migration of trophoblasts. Results: RGD-modified hydrogels showed dose-dependent binding to αIIbβ3. Both hydrogel and antibody treatments significantly reduced antiphospholipid antibodies (aPL)-induced platelet aggregation, delayed fibrin clot formation, and suppressed IL-6 and TNF-α release from trophoblasts. Cell migration assays confirmed that these interventions preserved trophoblast motility impaired by aPL exposure. Conclusion: Targeting integrin αIIbβ3 with RGD-functionalized biomaterials or neutralizing antibodies effectively attenuated aPL-mediated thromboinflammation. This approach represents a promising localized intervention strategy to prevent APS-related pregnancy complications.

Abstract: Background: Alzheimer’s disease (AD) progresses silently, with pathological changes such as amyloid-beta (Aβ) accumulation occurring years before cognitive symptoms emerge. Early intervention is considered critical to modifying disease progression. However, conventional therapeutics often lack pathological specificity and cause systemic side effects, highlighting the need for disease-responsive strategies. Methods: We designed a BACE1-cleavable peptide precursor that self-assembles into nanofibers in Aβ-rich environments. Enzyme-triggered assembly was characterized using dynamic light scattering (DLS) and Thioflavin T (ThT) fluorescence. Neuroprotective effects were assessed via MTT assay and qPCR of inflammatory markers. Results: The responsive peptide formed stable nanostructures upon BACE1 activation, significantly suppressed Aβ aggregation, improved neuronal viability, and reduced IL-1β expression. Conclusion: This study validates the use of enzyme-responsive peptide nanofibers as a selective and multifunctional therapeutic strategy for early intervention in Alzheimer’s disease, combining disease-environment activation with anti-aggregation, anti-inflammatory, and cognitive protective effects.

Abstract: Background: Parkinson’s disease involves progressive dopaminergic neuron degeneration and elevated oxidative stress. Targeted delivery of neurotrophic factors like glial cell line-derived neurotrophic factor (GDNF) remains a therapeutic challenge due to the need for site-specific, stimulusresponsive release. Methods: We developed a reactive oxygen species (ROS)-responsive hydrogel designed to release GDNF upon exposure to oxidative signals. The hydrogel’s degradation behavior and release kinetics were assessed under physiological and oxidative conditions. Bioactivity of the released GDNF was evaluated in vitro using ROS-damaged neuronal cells. Results: The hydrogel showed high stability under normal conditions but degraded rapidly in the presence of H₂O₂, enabling dose-dependent GDNF release. Released GDNF retained biological activity, promoting neuronal survival and neurite extension. Conclusion: This ROS-responsive hydrogel represents a promising platform for oxidative stress-triggered neurorepair and site-specific neuromodulation in Parkinson’s disease therapy.